by Scott Larrivee | Jan 10, 2025 | News
High-volume, breakthrough radioisotope production platform to enable innovation in life sciences and industrial applications VALENCIA, Calif. – January 10, 2025 – Nusano, a privately held physics company transforming the production of radioisotopes utilized in...
by Scott Larrivee | Dec 9, 2024 | News
VALENCIA, Calif. and SYDNEY, Australia – Dec. 9, 2024 – Nusano, a physics company transforming the production of radioisotopes, and GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid...
by Scott Larrivee | Oct 1, 2024 | News
Funding supports development and commercialization of broad array of isotopes for medical, commercial and industrial uses VALENCIA, Calif. – Oct. 1, 2024 – Nusano, Inc., a physics company transforming the production of radioisotopes, today announced a Series C...
by Scott Larrivee | Jul 10, 2024 | News
VALENCIA, Calif. and BOCA RATON, Fla. – July 10, 2024 – Nusano Inc. (Nusano), a physics company transforming the production of medical radioisotopes, and PharmaLogic Holdings Corp. (PharmaLogic), a leading radiopharmaceutical contract development and manufacturing...
by Scott Larrivee | Sep 12, 2023 | Industry News
News from the United Kingdom’s Institute of Cancer Research (ICR) published in The Lancet Oncology reports that targeted radiation treatment is “greatly improving” the quality of life for cancer patients. ICR writes: Patients with advanced prostate...
